The Gulf Time Newspaper One of the finest business newspapers in the UAE brought to you by our professional writers and editors.
Bloomberg
Takeda Pharmaceutical Co agreed to pay as much as
$6 billion for an experimental immune therapy from Nimbus Therapeutics, part of the Japanese drugmaker’s hunt for promising new products.
Takeda will pay $4 billion upfront for the drug, which is called NDI-034858 and will be renamed TAK-279, the companies said in a statement. Cambridge, Massachusetts-based Nimbus is also eligible for two milestone payments of $1 billion each if the drug reaches annual net sales of $4 billion and $5 billion.
Investors are looking for growth from Takeda since its $62 billion takeover of Shire five years ago. Chief Executive Officer Christophe Weber said the drug offers an opportunity to enhance its strategy beyond Entyvio: The ulcerative colitis treatment that generated about 15% of the company’s revenue for the year that ended in March.
The Nimbus drug inhibits an immune-related protein called tyrosine kinase and recently yielded positive results in mid-stage studies of moderate-to-severe plaque psoriasis. It’s expected to enter final-stage studies next year.